Karyopharm Therapeutics | KPTI - Ebitda


Karyopharm Therapeutics reported $-26.2M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Abbott USD 3.27B 178M Dec/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
J&J USD 7.19B 2.32B Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 6.3B 2.09B Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.3B 530M Mar/2026
Novartis USD 5.84B 235M Sep/2025
Pfizer USD 5.99B 5.23B Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Takeda JPY 150.25B 297.88B Mar/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
TG Therapeutics USD 51.69M 19M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Xencor USD -51.05M 55.28M Dec/2025